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BACKGROUND: Increasing reliance on non-medicinal interventions to control sea lice in the 19 
Atlantic salmon (Salmo salar) farming industry imposes a high level of skin mucosal 20 
disturbance and indirect health issues. Dietary supplementation with yeast-based MOS 21 
products is widely used to support intestinal homeostasis across farmed species. Evidence of 22 
their effect on skin mucosa is increasing in aquatic species but it remains inconsistent and 23 
someway short of a clear contribution to sea lice management. A tank-based trial was 24 
performed to test the effect of a yeast-based MOS functional compound (sMOS) on the skin 25 
mucosal layer and its protective effects against sea lice (Lepeophtheirus salmonis). 26 
RESULTS: The test compound significantly increased skin mucus (+46%) and goblet cell 27 
density (+25 %) after 6 weeks of dietary supplementation when positive effects on intestinal 28 
villi-length (+10.9 %) and goblet cell density (+80.0 %) were also documented. Following 29 
dietary supplementation, a 16.6 % reduction in susceptibility to an acute standard copepodid 30 
challenge was measured alongside an earlier increase in skin lysozyme activity widely used as 31 
an index of innate immunity.   32 
CONCLUSION: The study provides functional evidence that the benefits of dietary sMOS 33 
reach beyond the intestine to the skin mucosa. Bolstering of the Atlantic salmon skin barrier 34 
and immune functions and the resulting lower susceptibility to sea lice has the potential to 35 
reduce the need for delousing interventions and the impact of non-medicinal interventions on 36 
the animal’s health and welfare.  37 
 38 
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1. INTRODUCTION 41 
Naturally occurring sea lice (Lepeophtheirus and Caligus species) remains a major biological 42 
bottleneck to the expansion of the Atlantic salmon (Salmo salar) farming industry with 43 
Lepeophtheirus salmonis being the most prevalent and damaging species in the Northern 44 
hemisphere (Johnson et al., 2004; Torrissen et al., 2013). Recently, the industry has undergone 45 
a dramatic shift away from antiparasitic drugs in favour of non-medicinal interventions 46 
including hydrogen peroxide, freshwater, mechanical and thermal treatments (Overton et al., 47 
2019a), biological control using cleaner fish (Leclercq et al., 2014; Brooker et al., 2018) and 48 
preventive cage-based technologies coercing host-parasite mismatch (Frenzl et al., 2014; 49 
Oppedal et al., 2017, Stien et al., 2018). These are deployed in combination or in rotation and 50 
integrated within comprehensive sea lice management programs. Non-medicinal based sea lice 51 
management has proved successful at controlling sea lice while generating a 78 % reduction in 52 
chemical drug use between 2014 and 2017 in Norway (Helgesen et al., 2018). However, 53 
thermal and mechanical treatments have been associated with significant health, welfare and 54 
productivity penalties in the form of external injuries, gill damage, reduced growth and elevated 55 
mortalities (Helgesen and Jansen, 2018; Overton et al., 2019a, 2019b). Beyond any direct 56 
impacts, frequent repetitive handling is likely to chronically stress and compromise the 57 
animal’s physiological and immune status towards a higher risk of secondary infections 58 
(Nardocci et al., 2014). In this context and notwithstanding the continuous advancement of 59 
these novel methodologies, there is a renewed interest to bolster resilience to infectious and 60 
non-infectious challenges in an effort to reduce both the frequency and impact of delousing 61 
interventions.  62 
Functional feeds are defined as feeds with growth, health or other physiological benefits above 63 
and beyond the levels normally achieved when basal nutritional requirements are met (Jensen 64 




yeast cell wall (YCW) of the baker’s yeast (Saccharomyces cerevisiae) have been extensively 66 
trialled across the aquaculture sector, validating the distinct health benefits of yeast-derived β-67 
glucans and mannan-oligosaccharides (MOS). Yeast-derived β-1,3/1,6-glucans are conserved 68 
microbial structures recognized as non-self by the host innate immune system primarily via 69 
Dectin-1 receptors present in macrophages in mammals (Brown et al., 2003). No clear 70 
homologues to mammalian Dectin-1 have been identified in fish so far, but β-glucans have 71 
been shown to regulate a signalling pathway associated with C-type lectin receptor (CLR) and 72 
candidates β-glucan receptors with conserved Dectin-1 features have been identified (Petit et 73 
al., 2019). Upon recognition, β-glucan triggers a pro-inflammatory response stimulating 74 
phagocytosis and a number of other immune cells (Herre et al., 2004; Brown, 2006). Their 75 
potent immune-stimulatory effect is well documented in fish (Dalmo and Bøgwald, 2008; 76 
Meena et al., 2013; Kiron et al., 2016) and command a pulsed-feeding against the risk of 77 
immune desensitisation (Bricknell and Dalmo, 2005). Yeast-derived MOS-products have 78 
distinct properties and applications with three primary functionalities. Firstly, MOS function 79 
as direct blocking agents of enteropathogenic bacteria within the gut lumen preventing 80 
intestinal adhesion (Firon et al., 1983). Secondly, MOS are low-molecular-weight 81 
carbohydrates non-digestible by vertebrates but preferentially fermented by intestinal lactic 82 
acid bacteria. As such, they act as prebiotic and have indeed been shown to positively modulate 83 
the intestinal microflora in various aquaculture species (Dimitroglou et al., 2009; 2010; 2011a; 84 
Akter et al., 2016). Thirdly, yeast-derived MOS are ligands to pattern recognition receptors 85 
(PRRs) such as the endocytic mannose-receptor (MR) primarily expressed on macrophages 86 
and dendritic cells (Ringø et al., 2010). Far from being fully elucidated, the function of MR in 87 
host defence has been shown essential for both pro- and anti-inflammatory cytokines 88 
production and appears to be involved in an array of mechanisms including phagocytosis, 89 




Martinez-Pomares, 2009). These authors noted that “mannose is not a danger signal” and that 91 
“MR ligation is largely associated to the reduction of pro-inflammatory cytokines and 92 
resolution of inflammation”. The benefits of MOS on intestinal health and functions are overall 93 
well established (Torrecillas et al., 2014; Guerreiro et al., 2017) as recently confirmed in the 94 
European seabass (Dicentrachus labrax; Torrecillas et al., 2018) and using a rainbow trout 95 
(Oncorhynchus mykiss) intestinal epithelial cell line (RTgutGC) model (Wang et al., 2019). 96 
Beyond the local intestinal effects of dietary MOS, several studies showed elevated systemic 97 
(humoral) immunity including in European seabass (Torrecillas et al., 2007; 2011), red drum 98 
(Sciaenops ocellatus; Zhou et al., 2010), rainbow trout (Staykov et al., 2007) and freshwater 99 
species (Welker et al., 2011; Akrami et al., 2012; Razeghi et al., 2012; Liu et al., 2013). 100 
Evidence is also emerging of an effect of certain MOS products on the skin and gill mucosa 101 
and of enhanced protection against associated pathogens. Dietary MOS were reported to 102 
decrease the susceptibility of greater amberjack (Seriola dumerili) to the skin fluke 103 
Neobenedenia girellae (Fernández-Montero et al., 2019), increased survival of juvenile red 104 
drum when challenged with the marine ectoparasite Amyloodinium ocellatum (Buentello et al., 105 
2010) and channel catfish (Ictalurus punctatus) when challenged with Flavobacterium 106 
columnare with indications of mannose-associated signalling pathways recruitment, 107 
inflammatory resolution and enhanced epithelial repair documented in the gill (Zhao et al., 108 
2015). In rainbow trout, MOS increased skin mucus excretion, circulating immunity and 109 
survival to Aeromonas salmonicida (Rodriguez-Estrada et al., 2013). In Atlantic salmon, MOS 110 
significantly reduced sea lice susceptibility under a heavy natural challenge (Dimitroglou et al., 111 
2011b) but had no apparent effect under a moderate natural challenge using a distinct yeast-112 
based MOS product at lower incorporation rate (Refstie et al., 2010) as was also reported under 113 
controlled laboratory conditions (Jensen et al., 2014). Dietary MOS was found to affect the 114 




multi-functional protein directly involved in mucin synthesis (Micallef et al., 2017) with 116 
possible participation in immunity and T-cell adaptive response in particular (Porcellini et al., 117 
2006).  118 
The response of Atlantic salmon to sea lice infection involves a combination of chronic stress, 119 
impaired healing, innate and adaptive immune components (Mustafa et al., 2000; Skugor et al., 120 
2008). Interestingly, the expression of a MR (Macrophage mannose receptor 1, MRC1) and of 121 
several mucins were recently found highly up-regulated at sea lice attachment site suggesting 122 
increased mucus secretion and a possible route to enhancing protection (Robledo et al., 2018). 123 
Similarly, mechanical wound-healing in Atlantic salmon involves mucous cell recruitment at 124 
the border of the healing wound and secretion of an adherent mucous layer in concomitance 125 
with a characteristic early innate immune response (Sveen et al., 2019).  126 
Accumulating evidence of an effect of MOS on skin mucosal surface and of enhanced 127 
protection against external pathogens support the concept of cross-communication towards a 128 
degree of cross-protection between mucosal barriers (Iijima and Kiyono, 2001; Salinas et al., 129 
2011; Rombout et al., 2014). The prospect that the established effects of MOS on intestinal 130 
homeostasis and immunity may, in part, cross-over to the skin mucosa raises strong interest 131 
particularly towards enhanced sea lice protection and wound-healing in Atlantic salmon. 132 
However, published studies on the effect of MOS on Atlantic salmon skin mucosa remains 133 
surprisingly seldom and with contrasting findings therefore warranting further attention given 134 
the current challenges faced by the industry. 135 
The aim of the study was to document the effect of a specific MOS product on the skin barrier 136 
function and susceptibility of Atlantic salmon to sea lice while documenting the relationship 137 
between intestinal, skin health and sea lice protection as a prerequisite to any further 138 





2. MATERIAL AND METHODS 141 
Animals were investigated and handled in accordance with the Animals (Scientific Procedures) 142 
Act 1986 (ASPA) revised to transpose European Directive 2010/63/EU as currently in force 143 
since 1 January 2013 in Scotland. 144 
 145 
2.1 System and fish 146 
The experiment was carried out at the Machrihanish Marine Environmental Research 147 
Laboratory (MERL; Institute of Aquaculture, University of Stirling, Scotland, UK) within a 148 
flow-through indoor tank system (600 L circular, self-cleaning central drain) supplied with 149 
pumped-ashore, pre-treated natural seawater under a simulated natural photoperiod (16:8 h 150 
light:darkness). Water flow was set at 2 L/min and individual tanks equipped with oxygen-151 
sensor. Dissolved oxygen saturation was maintained above 80 %, water temperature and 152 
salinity were measured daily and averaged 14.1 ± 0.4 °C and 33.9 ± 0.3 ppt respectively over 153 
the trial’s duration. Following on-site acclimation, locally sourced Atlantic salmon post-smolts 154 
(Buckieburn hatchery, Stirling, Scotland, UK) originating from a single size-graded population 155 
were randomly distributed into the experimental units (40 fish / tank; mean initial body-weight, 156 
BWi = 252 ± 4 g; mean intra-tank and inter-tank coefficient of variation; CVintra = 16.0 ± 1.8 %; 157 
CVinter = 1. 69 % at trial’s start).  158 
 159 
2.2 Experimental design and sea lice challenge 160 
The trial lasted 65 days testing two diets in quadruplicate: a basal diet (control diet) and the 161 
same basal diet supplemented pre-extrusion with a specific commercial MOS product 162 
incorporated at 4 kg/T feed pre-extrusion (sMOS diet; Lallemand SAS, Blagnac, France). This 163 
product is obtained from the primary fermentation of S. cerevisiae and typically contains 26 % 164 




of proteins. The structure of this YCW product shows 26 % of interaction with an Atomic Force 166 
Microscopy (AFM) tip functionalised with Concanavalin A (a lectin binding to α-mannose 167 
units), mannan-chains of unfolded median length of 32 nm and a mean elasticity’s modulus of 168 
637 kPa.   169 
The basal diet was formulated to the Atlantic salmon post-smolt requirements, the diets were 170 
prepared by BioMar (Ø 3 mm; Tech-Center, Brande, Denmark), randomly allocated to one of 171 
four experimental units and hand-fed to visual satiation 5 to 6 times daily over the trial’s 172 
duration. Mortalities were removed daily and did not exceed 5 % / tank (2 fish / tank) over the 173 
trial’s duration. A standard sea lice (SL) infection challenge was performed at day 46 using 174 
laboratory bred free-swimming L. salmonis copepodids. Within each tank, fish were crowded 175 
to half the initial rearing volume, exposed to an acute standard copepodid challenge (3,000 176 
copepodids / tank) and maintained for 2 h under low water volume, low water exchange to 177 
favour parasite settlement. 178 
 179 
2.3 Sampling schedule  180 
At stocking (T0; trial start), all fish were individually measured for BW (± 0.1 g) and fork-181 
length (FL; ± 1 mm) under light sedation (MS-222, 30 ppm, ~ 1 min). Two days prior SL-182 
challenge (T1; T0 + 44 days), 10 fish / tank were randomly netted and sedated for BW and FL 183 
measurements, of which 4 fish were returned to their original tank following intermediary 184 
recovery holding and 6 fish were sampled for skin mucus prior being sacrificed by cranial 185 
concussion for skin and intestinal tissue sampling. One week after SL-challenge (T2; T0 + 53 186 
days); 15 fish / tank were randomly netted and sedated for measurement of BW, FL and SL 187 
assessment, of which 9 fish were returned to their original tank and 6 fish were sacrificed for 188 
skin mucus and tissue sampling. At the end of trial (T3; T0 + 65 days), all remaining fish (17 to 189 




randomly selected for SL assessment and skin mucus sampling, and of those 6 fish / tank were 191 
randomly selected for skin and intestinal tissue sampling.   192 
 193 
2.4 Sampling procedures  194 
Sea lice assessment was performed blindly by the same two trained scientists at all time-points 195 
with fish carefully examined using a macroscope. For each fish examined (15 fish / tank / time-196 
point T2 and T3), the number and life-stage of sea lice was determined and skin mucous was 197 
sampled after body-size (T1) or sea lice (T2 and T3) assessment from the left-side flank 198 
preserved from any unnecessary handling disturbance. After removing any sea lice using a 199 
tweezer, a spatula was consistently wiped over a standard body-area, i.e. from the edge of the 200 
operculum to the anal pore, and the accumulating mucus transferred into a 1 ml pre-weighed 201 
syringe, weighted (± 0.001 g) and snap-frozen at -80 °C until further analysis. The collected, 202 
crude skin mucus weight was expressed relative to individual fish standard length (mg of 203 
mucus / cm of fish) for comparison of relative skin mucus level between experimental groups. 204 
Skin and distal intestine were sampled as follow. A skin sample of ~1 cm2 was excised from 205 
the dorsal region between the head and dorsal fin. A transversal section of distal intestine (~1 206 
cm length) was then excised, stripped of digesta and washed in PBS. Skin and intestinal sample 207 
were fixed in 10 % formalin, kept at 4 °C for 48 hours prior storage in 70 % ethanol at 4 °C 208 
until processing. 209 
 210 
2.5 Analytical protocols 211 
Skin mucous protein concentration was determined using a Protein Assay kit (PierceTM BCA, 212 
ThermoFisher Scientific) in accordance with the manufacturer’s recommendations. Lysozyme 213 
activity of the epidermal mucus was determined using a turbidimetric assay based upon the 214 




and intestinal samples were processed following standard histological procedures. In brief, 216 
samples were dehydrated, embedded in paraffin wax for transversal sectioning at 5 μm 217 
thickness and stained with combined haematoxylin eosin, alcian blue and van Gieson to ensure 218 
visible contrast between mucin cells and the surrounding tissue. Images were captured on a 219 
Leica DMD 108 digital microscope at x40 magnification for measurement of the following 220 
parameters by image analysis (Image J 1.47v, National Institutes of Health, Bethesda, 221 
Maryland, USA). From the distal intestine sections (2 sections/fish), villus height was 222 
determined as the average height of four complete villus; lamina propria width was calculated 223 
as the average of three measurements per villi (bottom, middle and top of the villi) from four 224 
complete villus; and goblet cell abundance determined across a 200 μm length of five distinct 225 
villus starting from the apex (Fig. 1a). Goblet cell coverage in the intestinal tissue section was 226 
performed by computer-assisted image analysis (Image J 1.47v) for automated measurement 227 
of tissue surface area on a black and white image and of goblet cell coverage on the same 228 
fluorescent image (Fig. 1b, 1c). From the skin sections (2 sections/fish), goblet cell abundance 229 
was measured across a 400 µm section from the tip of a scale pocket (Fig. 2a).  To determine 230 
goblet cell coverage (%), an in-house script was used (Image J 1.47v) for automated goblet cell 231 
separation onto a white background (Fig. 2b) and determination of the total area covered by 232 
goblet cells. The area of the dermis was then measured on the original image using the 233 
freehand-draw tool (Fig. 2c) to calculate goblet cell coverage as follows: Goblet cell coverage 234 
(%) = (total area of goblet cells ÷ dermal tissue area) x 100.  235 
 236 
2.6 Calculations and statistics  237 
Fulton’s condition factor (K) was calculated as K = (100 BW) / FL3 with BW (g) and FL  (cm); 238 
specific growth rate (SGR) as SGR (% / day) = 100 (eg - 1); where g = (LnBWf −LnBWi)/t; 239 




duration (day); thermal growth coefficient (TGC) as TGC = 1000 ((BWf1/3 - BWi1/3) /dd) where 241 
dd is the total degree-day over the trial’s duration. 242 
A 1-way analysis of variance (ANOVA) manipulated by a general linear model was applied to 243 
test the effect of diet on body-size parameters at trial start and end as well as growth indices 244 
over the trial’s duration. A mixed linear ANOVA model was applied on skin mucus, histology 245 
parameters and lice count with diet and time as fixed factor and tank as random factor. Prior 246 
analyses, proportions were arcsin-transformed; datasets were checked for normality using the 247 
Kolmogorov–Smirnov test and for homogeneity of variance using Levene’s test. Where 248 
differences occurred, post-hoc analyses were carried-out using Bonferroni-corrected t-test. 249 
These statistical analyses were applied using IBM® SPSS® Statistics v24.  Linear regression 250 
between relative skin mucus level pre-challenge (T1) and sea-lice count at T2 (7-day post 251 
challenge) were conducted using SigmaPlot v11.0 to test the significance of the linearity and 252 
determine the adjusted R-squared (R2) value of the regression model using relative skin mucus 253 
level as an independent variable and sea-lice count as a dependent variable. A significance 254 
level of 5 % (p < 0.05) was applied, data are presented as mean ± SEM of replicates tanks. 255 
 256 
3. RESULTS 257 
3.1 Performance 258 
There was no statistical difference in body-size parameters between groups at the start of the 259 
trial (Table 1a). The test diets had no significant effect on body-sizes and growth but a trend 260 
for a positive effect of sMOS diet on SGR and TGC (+ 11.3 %) was observed and associated 261 
with a better maintenance of Fulton’s condition factor at the end of the trial (Table 1b). 262 
 263 




Distal intestine villi length (Fig. 3a) was significantly higher in the sMOS compared to the 265 
control group across time (+ 10.0 ± 4.6 %; p = 0.028), prior, as well as 3 weeks after the SL-266 
challenge. Goblet cell density and coverage were also significantly higher in the sMOS 267 
compared to control group across time (Fig. 3b; + 65 ± 26 %; p < 0.001; + 31 ± 21 %, p < 0.01 268 
respectively across time) and statistically decreased following the sea lice challenge (T2 269 
compared to T1) in both treatments. Subsequently at T3, goblet cell density returned to pre-270 
challenge levels and their coverage remained stable in the control while both parameters further 271 
decreased in the sMOS group although remaining significantly higher than in the control at that 272 
time point (+ 35.1 % and + 25.2 % respectively; p < 0.001).   273 
 274 
3.3 Skin mucus and histology 275 
There were significant overall diet effect in the form of higher relative skin mucus level (Fig. 276 
4a; + 22.8 ± 12.2 %; p = 0.002), goblet cell density (Fig. 4b; + 10.7 ± 7.1 %; p < 0.001) and 277 
goblet cell coverage (Fig. 4c; + 41.0 ± 25.4 %; p = 0.029) in the sMOS compared to control 278 
group across time-points. Skin mucus level was significantly higher in the sMOS compared to 279 
the control prior as well as 3 weeks after the SL-challenge (T1: + 46.2 %; p = 0.019; T3: +15.1 %; 280 
p = 0.018) and remained steady over time in both treatments. Similarly, goblet cell coverage 281 
was significantly higher in the sMOS group prior and 3 weeks after the challenge (T1: + 81.1 %; 282 
p < 0.001; T3: + 48.1 %; p = 0.007) with a transient increase and a transient decrease were 283 
observed at 7-days post challenge (T2) in the control and sMOS group respectively. In 284 
comparison, goblet cell density was significantly higher in the sMOS group at pre-challenge 285 
only (+ 24.5 %; p < 0.001) and increased following the sea lice challenge in the control.  286 
The skin mucus protein concentration was not affected by diet (p = 0.266) but significantly 287 
varied over time (Fig. 5a; p < 0.001) showing in both groups a transient increase 7-days post-288 




T3. Skin lysozyme activity (Fig. 5b) significantly varied over time (p < 0.001) being, in 290 
particular, 2.2-fold higher at T3 compared to T1 across experimental groups. Further, there was 291 
a significant overall diet effect (p = 0.012) being significantly higher in the sMOS compared 292 
to the control group at T2 (+ 203 %; p < 0.001). At that time, lysozyme activity remained at 293 
pre-challenge level in the control but had increased to levels observed at T3 in the sMOS group, 294 
albeit with a high variability across rearing suggesting the onset of lysozyme up-regulation. 295 
 296 
3.4 Sea lice count  297 
Sea lice development was homogenous within and between tanks at each time-point with all 298 
stages being chalimus at 7-day post-challenge (T2) and pre-adult at 3-week post-challenge (T3; 299 
data not shown). There was an overall significant effect of diet on sea lice count (p = 0.002) 300 
being significantly lower in the sMOS compared to the control group at T2 (-16.6 %; p = 0.004) 301 
but not T3 (-9.8 %; p = 0.152). Sea lice count significantly decreased between T2 and T3 in the 302 
control only (Fig. 6; Control: - 16.2 %, p = 0.005; sMOS: - 9.4 %, p = 0.175). There was a 303 
weak negative relationship between relative skin mucus level pre-challenge (T1) and sea lice 304 
count at T2 (correlation coefficient r = - 0.587; r2 = 0,345; adjusted-r2 = 0.214; p = 0.166). 305 
 306 
4. DISCUSSION 307 
Using a limited number of practical parameters, the study provided applied scientific evidence 308 
indicating that sMOS supplementation reinforced the skin mucosa prior and in response to sea 309 
lice resulting in enhanced protection against the larval chalimus stage. No negative impact of 310 
the diet on growth was observed but a positive impact on the intestinal cyto-architecture was 311 
confirmed. This supports emerging evidence that the protective effects of dietary yeast-based 312 
MOS reach beyond the intestinal to the skin mucosa and warrants further research on the 313 





4.1 Intestinal cytoarchitecture and growth 316 
The effects of yeast-based MOS products on the intestinal cytoarchitecture, i.e. increased villi-317 
height and goblet cell density, were previously reported in various aquaculture species 318 
including salmonids (Refstie et al., 2010; Dimitroglou et al., 2011b; Rawling et al., 2017) and 319 
are widely associated with enhanced intestinal health and functions. In particular, a higher 320 
goblet cell density and surface coverage suggest a higher level of mucus secretion which has 321 
an essential role in lubricating food passage and providing physical protection to the underlying 322 
intestinal wall against external damage from e.g. toxins and infectious agents (Pérez-Sánchez 323 
et al., 2013). More than a simple static physical barrier, goblet cell-secreted mucus actively 324 
sustain mucosal epithelial homeostasis by promoting the growth and maintenance of epithelial 325 
cells and therefore act as an integral player in innate and adaptive immunity in particular 326 
delivering foreign luminal antigens to lamina propia dendritic cells (Shan et al., 2013; 327 
Pelaseyed et al., 2014; McCauley and Guasch, 2015). Being immuno-driven, increased 328 
intestinal surface area using functional yeast fractions is expected to convey superior animal 329 
performance in particular when exposed to challenging conditions. In this study, the apparent 330 
improvement in growth (+11.3% in SGR) and maintenance in condition (K) measured with the 331 
sMOS diet was particularly encouraging considering the short-duration of the pre-challenge 332 
phase and the acute sea lice challenge applied. However, the growth achieved over the trial’s 333 
duration was insufficient (below 2-fold increase in body-weight) to appropriately assess a diet 334 
effect on performance; and this was due to the repetitive interventions inherent to the 335 
experimental aims.  336 
 337 




Following 6 weeks of dietary supplementation and prior to sea lice challenge, sMOS was 339 
associated with higher levels of skin mucus secretion, goblet cell density and relative surface 340 
area with no alterations in the mucus protein concentration and lysozyme activity. At that time, 341 
the apparent proliferation of epidermal goblet cells by dietary sMOS was concomitant with 342 
observations in the intestinal mucosa. Such coinciding responses across distinct mucosal 343 
tissues corroborate the concepts of an integrated mucosal immune response whereby the 344 
different mucosal-associated lymphoid-tissue (MALT) are inter-linked and cross-communicate 345 
with stimulation of one MALT resulting in similar responses in other distant MALT (Iijima 346 
and Kiyono, 2001). This arena primarily refers to mucosal anti-body response in the context of 347 
oral or mucosal immunization against targeted pathogens with evidence of cross-mucosal 348 
response in various studies; albeit with a clear compartmentalization within and between 349 
MALTs (Salinas et al., 2011). Recently, different studies in aquaculture species have reported 350 
enhanced anti-microbial defense of the skin using in-feed functional ingredients (e.g. Cerezuela 351 
et al., 2016; Micallef et al., 2017; Saeidi et al., 2017). However, this is the first report of a diet-352 
induced proliferation of goblet cells co-occurring in the local gut and distal skin epithelium. 353 
This reinforces the notion of inter-connectivity between intestinal and external mucosa and 354 
strengthens current evidence of a contribution of yeast-based functional ingredients beyond 355 
their intestinal effect.  356 
Thicker skin mucus coverage is expected to provide a stronger physical barrier against sea lice 357 
settlement. Indeed, infective L. salmonis copepodids initially settles to the host using hooked 358 
second antennae driven into the epidermis, followed by attachment to the epithelial basement 359 
via a new frontal filament produced at each chalimus molt (Bron et al., 1991; Gonzáles-Alanis 360 
et al., 2001). Accordingly in this study, a higher relative skin mucus level and goblet cell 361 
coverage at time of copepodid challenge (T1) was observed alongside a significantly lower 362 




relationships between skin mucus level and chalimus count were not statistically significant 364 
suggesting the contribution of other protective factors in the skin mucus. With sessile chalimus 365 
predominantly feeding on skin mucus (Heggland et al., 2020), differences in susceptibility may 366 
also pertain to the presence, in the skin mucus, of immune relevant molecules (Brinchmann, 367 
2016) or of other factors such as of agents blocking the secretion of protease from L. salmonis 368 
(Fast et al., 2003). Further studies should address the dietary modulation of skin mucus 369 
composition by the MOS product tested in this study in both naïve and infected Atlantic salmon.  370 
 371 
4.3 Skin mucosal response to sea lice and diet effect 372 
The host mucosal response to sea lice, as observed in the control group, did not involve an 373 
apparent alteration in the level of skin mucus excretion but was characterized, within 7 days of 374 
copepodid exposure, by a rapid proliferation of skin goblet cells accompanied by a transient 375 
increase in goblet cell coverage and mucus protein concentration together indicating a 376 
reinforcement of the skin physical barrier. This apparent primary response partly dissipated at 377 
a later stage and upon the recruitment of antimicrobial-defence, i.e. increased lysozyme activity, 378 
which could constitute a more steady state response to an established, mobile stages infection 379 
as observed at T3 in this study.  380 
In comparison in the sMOS group, estimated skin mucus level and goblet cell coverage initially 381 
decreased to the values measured in the control group following copepodid exposure. This 382 
temporary loss of beneficial dietary effect may have been linked to handling and short-term 383 
starvations associated with the challenge protocol or to the immune-modulation of the host by 384 
the parasites secretory/excretory system. Indeed, L. salmonis secrete different 385 
immunomodulatory compounds to evade the host immune response (Firth et al., 2000; Fast et 386 
al., 2007; Fast 2014; Hamilton et al., 2018) and these may have more active and discernible 387 




challenge. In any case, these suppressions were only transient and not below the basal levels 389 
observed in the control group. Interestingly, goblet cell density remained consistently high with 390 
no further proliferation upon sea lice exposure while an earlier increase in lysozyme activity 391 
was observed compared to the control together indicating the preparation and reinforcement of 392 
the skin mucosal response to sea lice by the sMOS product tested.  393 
 394 
4.4 Continuous lice protection 395 
A significant 16.6 % reduction in copepodid settlement, as measured at the chalimus stage, was 396 
achieved by the test compounds under the controlled conditions of the study. Surprisingly few 397 
studies have tested the effect of yeast-based functional ingredients against sea lice in general 398 
and L. salmonis in particular. Previous studies using yeast-based MOS products showed 399 
contrasting results varying from significant reductions to no apparent effects (Refstie et al., 400 
2010; Dimitroglou et al., 2011b; Covello et al., 2012; Jensen et al., 2014) albeit under a variety 401 
of trials’ set-up. The phytochemical glucosinolate reduced L. salmonis by 17 % to 25 % (Jodaa 402 
Holm et al., 2016), a commercial product containing plant-derived compounds reduced Caligus 403 
rogercresseyi count by ~22 % (Nùñes-Acuña et al., 2015) and an oil-top coated commercial 404 
mixture of natural identical compounds reduced L. salmonis infection by up to 20 % (Jensen et 405 
al., 2014). Non-specific immune-modulators that potentiate the host innate immunity system 406 
and allow continuous preventive applications such as MOS (this study, Torrecillas et al., 2014) 407 
evidently have a distinct role and expected level of efficacy compared to short-term 408 
intervention therapies against sea lice. Besides their potential benefits against other infectious 409 
agents, the efficacy of preventive solutions over a single sea lice infection challenge does not 410 
express their actual benefit over their intended continuous application. Salmon-lice 411 
propagation is essentially host-density dependant such that the infection pressure within a farm 412 




Aldrin et al., 2018). Accordingly, commercial sea-sites typically experience limited events of 414 
salmon lice recruitment from wild hosts but often suffer from successive infection waves and 415 
on-site amplification of their internal or local lice population. In that context, the impact of 416 
continuous mitigation measures on the standing parasite population will also amplify over its 417 
successive generations. This could be expressed as a cumulative efficacy coefficient Cn = 1 - 418 
(1-c)n; where c is the efficacy of the control method against parasite-host colonization and n 419 
the number of generation or infection wave for which the method is applied. In the present 420 
study, sMOS had a 16.6 % efficacy against sea lice settlement translating, at the 3rd and 5th 421 
internal wave of infection into a reduction of the standing lice population of C3 = 42 % and C5= 422 
60 % respectively. This corresponds to the approximate number of successive generations of 423 
salmon-lice over the 6 to 9 month warmer-water period in Southern Norway and Scotland 424 
based on a generation time of 4 weeks at 18 °C to 8-9 weeks at 6 °C (Hayward et al., 2011) 425 
and 7 week at 12 °C (Tully; 1989). Such cumulative efficacy would remain valid regardless of 426 
the frequency or efficacy of any successive intervention therapies over the period and applies 427 
to each salmon-lice cohort from their initial recruitment from wild-stock. It illustrates that the 428 
residual salmon lice population will be increasingly lower as the grow-out cycle progress under 429 
a scenario of self-reinfection and co-infection with neighbouring sea-sites, ultimately reducing 430 
the frequency of interventions where such continuous strategies are applied.  431 
Beyond sea lice susceptibility, increased mucosal robustness in the form of a thicker skin 432 
mucus layer and of bolstered mucosal immunity, as documented here with dietary sMOS, is 433 
expected beneficial against the risk of mucosal damages and of secondary infections associated 434 
with direct and stress-related impact of non-medicinal interventions and handling. The practical 435 
health and welfare contribution of such prophylactic functional ingredients could be quantified 436 





5. CONCLUSION 439 
In conclusion, dietary sMOS induced goblet cell proliferation in the distal intestine and skin 440 
mucosa, promoted skin mucus excretion and an earlier up-regulation of its lysozyme activity 441 
which were associated with a lower susceptibility to the larval chalimus stage of the sea lice L. 442 
salmonis. Such practical evidence of a dietary enhancement of the skin mucosal defence by 443 
sMOS supports its contribution against sea lice propagation and suggests its broader 444 
contribution as prophylactic functional ingredients in support of mucosal integrity, animal 445 
health and welfare under repetitive handling conditions. 446 
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K: Condition factor, SGR: Specific growth rate; TGC: Thermal growth coefficient; T0, T1 and 721 
T4: Sampling points 0 (trial start), 1 (day 44, 2 days prior sea lice challenge) and 4 (trial end) 722 
respectively. 723 
  724 
        Control sMOS 
a. Body and population size parameters  
 Initial (T0; day 0)    
  Body-weight (g) 255 ± 2 249 ± 1 
  Fork-length (cm) 28.5 ± 0.1 28.5 ± 0.1 
  Fulton’s K  1.09 ± 0.02 1.07 ± 0.01 
 
 Population  (n/tank) 40 40 
 Pre-challenge (T1; day 44)  
  Body-weight (g) 38.9 ± 2 38.5 ± 2 
  Fork-length (cm) 32.7 ± 0.4 32.6 ± 0.4 
  Fulton’s K  1.10 ± 0.03 1.10 ± 0.03 
  Sampled population  (n/tank) 10 10 
 End-point (T4; day 65)   
  Body-weight (g) 399 ± 19 408 ± 12 
  Fork-length (cm) 33.7 ± 0.2 33.6 ± 0.3 
  Fulton’s K  1.04 ± 0.04 1.07 ± 0.01 
    Population  (n/tank) 17 ± 1 18 ± 0 
b. Growth performance  
 Pre-challenge period (T0 to T1)  
  SGR (%/day) 0.98 ± 0.11 1.00 ± 0.07 
  TGC  1.54 ± 0.19 1.57 ± 0.11 
 Challenge period (T1 to T4)  
  SGR (%/day) 0.11 ± 0.39 0.29 ± 0.09 
  TGC  0.18 ± 0.62 0.46 ± 0.15 
 Whole trial (T0 to T4)   
  SGR (%/day) 0.68 ± 0.07 0.76 ± 0.04 




FIGURES LEGENDS 725 
Figure 1: Transversal cut of Atlantic salmon distal intestine illustrating a) the measurements 726 
performed for cyto-architecture assessment: Lamina propria (LP) width, mucosal fold height, 727 
and goblet cell density (n / 200 µm from villi apex) and image transformation to determine b) 728 
tissue surface area (white) and c) goblet cell surface area (fluorescent) for calculation of goblet 729 
cell coverage (%) in the intestinal tissue section. Scale bar represents 100 µm. sm: sub-mucosa; 730 
mp: muscularis propia. 731 
  732 




Figure 2: Transversal cut of Atlantic salmon skin illustrating a) goblet cell density 733 
measurement (n / 400 µm) and image transformation to determine b) goblet cell surface area 734 
(black surface area) and c) dermis surface area (purple outline) for calculation of goblet cell 735 
coverage (%) in the skin section. Scale bars represent 100µm. d: dermis, Sc: scale; m: muscle. 736 
  737 













































































Figure 3: Distal intestine a) fold-length and b) goblet cells density at T1 (day 44); T2 (day 53) 738 
and T3 (day 65) with sea lice challenge applied at day 46. Dot-plot of individual data (grey bar); 739 
box-plot of individual data and mean ± SEM of replicate tanks mean (n =4; black-dot). 740 
Different letter indicate significant differences between groups and time-points. 741 
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Figure 4: a) Relative skin mucus level; b) goblet cell density and c) goblet cell coverage in the 743 
epidermis at T1 (day 44); T2 (day 53) and T3 (day 65) with sea lice challenge applied at day 46. 744 
Dot-plot of individual data (grey bar); box-plot of individual data and mean ± SEM of replicate 745 
tanks mean (n =4; black-dot). Different letter indicate significant differences between groups 746 
and time-points. 747 
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Figure 5: Skin mucus a) protein concentration and b) lysozyme activity at T1 (day 44); T2 (day 749 
53) and T3 (day 65) with sea lice challenge applied at day 46. Dot-plot of individual data (grey 750 
bar); box-plot of individual data and mean ± SEM of replicate tanks mean (n =4; black-dot). 751 
Different letter indicate significant differences between groups and time-points. 752 
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Figure 6: Sea lice count showing box-plot of individual fish count, dot-plot (grey bar) of mean 755 
sea lice count per tank and mean ± SEM of replicate tank per treatment and time-point (n =4 756 
with 15 fish/tank/time-point assessed). Different letter indicate significant differences between 757 
groups and time-points. 758 
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Skin mucus level pre-challenge (T1; mg/cm)
Figure 7: Relationship between mean relative skin mucus level pre-challenge (T1) and mean 760 
sea-lice count 7-day post challenge (T2) within individual tanks. The linear regression model 761 
had an adjusted-r2 value of 0.214 and was not significant (p = 0.166). 762 
 763 
